

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:

PRABHAKAR, Bellur S.

Application No. 10/572,582

Filed: March 20, 2006

Confirmation No.

Group Art Unit: Unassigned

Examiner: Unassigned

For: METHODS AND COMPOSITIONS OF
IG20 AND DENN-SV SPLICE
VARIANTS

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The Information Disclosure Statement is being filed:

- ☒ **within** any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- ☐ **after** (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:
- ☐ the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
- or*
- ☐ the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
- ☐ **after** the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under

First Named Inventor: PRABHAKAR, Bellur S.
Application No. 10/572,582

37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

- ☐ **after** the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and **within** thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

Copies of the References

- ☒ Copies of all foreign patents and non-patent literature listed on the enclosed Form 1449 are enclosed herewith.
- ☐ Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
- ☒ A copy of the international search report is enclosed herewith.
- ☐ The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLICATIONS		Status (<i>check one</i>)		
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1.				
2.				
3.				

Fees

- ☒ **No fee** is owed by the applicant(s).
- ☐ Charge Deposit Account No. 12-0913 in the amount of \$.


First Named Inventor: PRABHAKAR, Bellur S.
Application No. 10/572,582

Authorization to Charge Additional Fees

☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-0913.

Respectfully submitted,

Date: July 13, 2007




Alice O. Martin, Reg. No. 35,601
BARNES & THORNBURG LLP
P.O. Box 2786
Chicago, Illinois 60690-2786
(312) 357-1313 (telephone)
(312) 759-5646 (facsimile)

CERTIFICATION UNDER 37 CFR 1.8

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being electronically filed via EFS WEB addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Date: July 13, 2007



Mark J. Sweetin

Substitute for FORM 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number:	10/572,582
Filing Date:	March 20, 2006
First Named Inventor:	PRABHAKAR, Bellur S
Group Art Unit:	
Confirmation Number:	
Examiner Name:	
Attorney Docket Number:	21726-103049

U.S. PATENT DOCUMENTS

		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	A A	Al-Zoubi et al., "Contrasting Effects of IG20 and its Splice Isoforms, MADD and DENN-SV, on Tumor Necrosis Factor α -induced Apoptosis and Activation of Caspase-8 and -3," <i>Jrnl. of Biological Chem.</i> , 276:50 47202-47211 (2001)		
	A B	Efimova et al., "Differential Effects of IG20 and Its Splice Isoform, DENN-SV, on Cell Proliferation and Apoptosis," <i>FASEB Jrnl.</i> , 16:5 A1083 (2002)		
	A C	Efimova et al., "IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs," <i>Oncogene</i> , 23:5 1076-1087 (2004)		
	A D	Hilger et al., "The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer," <i>Onkologie</i> , 25:6 511-518 (2002)		
	A E	Schievella et al., "MADD, a Novel Death Domain Protein That Interacts with the Type 1 Tumor Necrosis Factor Receptor and Activates Mitogen-Activated Protein Kinase," <i>Jrnl. of Biological Chem.</i> , 272:18 12069-12075 (1997)		
	A F	Zhang et al., "A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system," <i>Proc. Natl. Acad. Sci. USA</i> , 95: 2586-2591 (1998)		

CHDS01 AOM 407271v1

EXAMINER		DATE CONSIDERED	
----------	--	-----------------	--

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).